Genetic variant in visfatin gene promoter contributes to reduced risk of hepatocellular carcinoma in a Chinese population

Abstract

Knowledge on the role of gene variants in the visfatin promoter region in the hepatitis B virus (HBV)-related liver diseases is limited. In this study, we genotyped two potentially functional single nucleotide polymorphisms (SNPs) in the visfatin promoter region, -1535C > T (rs61330082) and -3187G > A (rs11977021), in 120 HBVrelated chronic hepatitis B (CHB) patients, 140 HBV-related liver cirrhosis (HBVLC) patients, 243 HBV-related hepatocellular carcinoma (HBV-HCC) patients, and 224 asymptomatic HBV carriers. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated by logistic regression. The results showed subjects with a TT genotype of -1535C > T had a significantly decreased risk of HBV-HCC related to the CC and CC + CT genotypes (adjusted OR = 0.493, 95% CI = 0.313-0.778; OR = 0.535, 95% CI = 0.362-0.791, respectively). A lowered risk also appeared in the comparison between allele T and allele C (OR = 0.734, 95%, CI = 0.581-0.950). However, these associations existed only in people with Zhuang ethnicity, but not in people with Han ethnicity. There were no significant associations between -3187G > A polymorphisms and the risk of HBV-related liver diseases. Our results suggested that visfatin -1535C > T polymorphisms might be associated with decreased risk of HBVHCC among the ethnic Zhuang population in Guangxi, China.